Loblaw Co (L.TO):

Summary

  • Loblaw (L.TO) closed at C$64.18 on July 10, 2026, compared with C$65.93 on June 26.
  • Over the latest 10 trading sessions, the shares declined C$1.75, or 2.7%.
  • The stock initially fell to C$61.69 on July 6, a 6.4% decline from June 26, before recovering strongly during July 7–10.
  • There was no major negative company announcement during the period. The decline appears primarily attributable to profit-taking, consumer-staples sector rotation and uncertainty before second-quarter earnings.
  • The late-period recovery indicates that investors continued to view Loblaw as a relatively defensive business supported by discount grocery demand, earnings growth and share repurchases.

10-Trading-Day Performance

DateClosing priceDaily change
June 26C$65.93−0.24%
June 29C$64.59−2.03%
June 30C$64.34−0.39%
July 2C$62.87−2.28%
July 3C$62.45−0.67%
July 6C$61.69−1.22%
July 7C$63.04+2.19%
July 8C$63.92+1.40%
July 9C$63.39−0.83%
July 10C$64.18+1.25%

Net movement: C$65.93 → C$64.18
10-session return: −2.7%
Low during period: C$61.05 intraday on July 6.

Key Drivers

1. Profit-taking after the June advance

Loblaw had risen from approximately C$63.38 on June 22 to C$66.20 on June 24, a gain of roughly 4.5% in two sessions. That rally left the stock vulnerable to short-term profit-taking.

The June 29–July 6 decline therefore partially reversed the preceding advance rather than representing a clear deterioration in Loblaw’s business.

2. Rotation away from defensive consumer staples

Loblaw is normally treated as a defensive stock because grocery and pharmacy demand is relatively stable.

During periods when investors become more comfortable with economic or market conditions, capital can rotate toward:

  • technology;
  • financials;
  • industrials;
  • other economically sensitive sectors.

That rotation can temporarily pressure grocery shares even when the company’s underlying earnings outlook has not changed.

3. Uncertainty ahead of second-quarter earnings

On July 2, Loblaw announced that it would release its second-quarter 2026 results on July 30. As earnings approach, investors tend to reassess:

  • food same-store sales;
  • Shoppers Drug Mart performance;
  • gross margins;
  • operating expenses;
  • consumer trade-down toward discount banners;
  • management’s full-year earnings guidance.

The July 2 announcement was not negative, but it may have focused attention on execution risks following Loblaw’s earlier revenue shortfall.

4. Mixed first-quarter fundamentals remained an overhang

Loblaw’s first-quarter revenue increased approximately 4% year over year to C$14.48 billion, but was below the C$14.55 billion analyst consensus cited by Reuters.

Key operating results were mixed:

Q1 2026 metricResult
RevenueC$14.48 billion
Revenue growthApproximately 4% YoY
Food same-store sales+2.4%
Drug retail same-store sales+4.1%
Adjusted EPSC$0.52
Full-year outlookHigh-single-digit adjusted earnings growth

Discount banners such as No Frills and Maxi continued to outperform, but cautious consumer spending and pressure on non-essential purchases remained concerns.

5. Share repurchases provided underlying support

Loblaw has authorization to repurchase up to approximately 58.1 million shares, equal to about 5% of outstanding shares, between May 8, 2026 and May 7, 2027.

Share repurchases reduce the public share count and can support earnings per share, although the actual price impact depends on the timing and size of purchases.

Price Pattern

The period had two distinct phases:

June 29–July 6: decline

The stock fell from C$65.93 to C$61.69, a drop of:61.6965.9365.93×100=6.4%\frac{61.69-65.93}{65.93}\times100=-6.4\%65.9361.69−65.93​×100=−6.4%

The selling was relatively persistent, suggesting profit-taking and sector rotation rather than a one-day reaction to a specific company announcement.

July 7–10: recovery

The stock then recovered from C$61.69 to C$64.18:64.1861.6961.69×100=+4.0%\frac{64.18-61.69}{61.69}\times100=+4.0\%61.6964.18−61.69​×100=+4.0%

The rebound suggests that buyers returned near C$61–C$62, likely attracted by Loblaw’s defensive earnings profile and upcoming share-repurchase support.

Valuation Logic

Loblaw’s valuation depends primarily on whether it can continue growing earnings faster than revenue through:

  • expansion of discount stores;
  • private-label sales;
  • pharmacy and healthcare services;
  • expense control;
  • share repurchases;
  • supply-chain productivity.

The principal valuation constraint is that grocery sales growth is relatively mature. Sustained multiple expansion requires continued margin improvement or stronger-than-expected earnings growth, rather than revenue growth alone.

Risks

  • Another quarterly revenue miss.
  • Lower food inflation reducing nominal sales growth.
  • Weak discretionary and front-store sales at Shoppers Drug Mart.
  • Higher labour, distribution and store-expansion costs.
  • Regulatory or political pressure on grocery pricing and margins.
  • Increased competition from Walmart, Costco, Metro and Empire.
  • Heavy capital spending reducing free cash flow available for repurchases.

Scenarios

ScenarioPossible interpretation
BullL.TO holds above C$63–C$64 and retests the C$66–C$67 area as Q2 earnings confirm high-single-digit EPS growth.
BaseShares remain between approximately C$61 and C$66 while investors wait for the July 30 earnings release.
BearA weak Q2 revenue or margin result pushes the stock below C$61, potentially reopening the C$58–C$60 range.

Actionable Takeaways

  • The 2.7% 10-session decline was moderate, but concealed a sharper 6.4% mid-period drawdown and subsequent recovery.
  • The movement was mainly a valuation and positioning adjustment, not a confirmed fundamental breakdown.
  • C$61–C$62 emerged as the immediate support zone.
  • C$65.50–C$66.50 remains the near-term resistance area.
  • The next significant company-specific catalyst is the July 30, 2026 second-quarter earnings release.
  • The positive thesis would be weakened by falling same-store sales, margin compression or a reduction in full-year earnings guidance.

Comments

Leave a Reply